Veteran biotech leaders John Maraganore and Clive Meanwell launched Corsera Health with a mission to prevent cardiovascular disease using a combination of AI-based risk prediction and RNA interference therapies. Their lead program targets PCSK9 and angiotensinogen and aims to initiate clinical trials by year-end. This endeavor marks a significant continuation of their impact on RNAi therapeutics following prior successes at Alnylam Pharmaceuticals and The Medicines Company.